HomeInvestors & MediaNews
- Potential for improvement of neuronal loss and behavioral deficits confirmed through preclinical studies
- A Phase 1 clinical trial of ABL301 is currently underway in the United States
Pangyo (South Korea) – April 8, 2025, ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, today announced that its global partner, Sanofi delivered an oral presentation on the preclinical data of ABL301 (SAR446159) at the AD/PD 2025 (International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders).
AD/PD 2025 is a conference dedicated to discussions on the diagnosis, prevention, drug development, and clinical trials for neurodegenerative diseases, including Alzheimer’s and Parkinson’s. This year, the event was held in Vienna, Austria, from April 1 to 5.
ABL301 is a bispecific antibody pipeline that enhances potential therapeutic efficacy against Parkinson’s Disease by effectively carrying the anti-alpha-synuclein antibody into the brain utilizing Grabody-B platform technology of ABL Bio. Grabody-B platform targets the insulin-like growth factor 1 receptor (IGF1R) to maximize Blood-Brain Barrier (BBB) penetration of potential therapies for various neurodegenerative diseases.
According to the preclinical data of the presentation, ABL301 does not interfere with the natural function of IGF1R and has been shown to promote the clearance of alpha-synuclein aggregates by microglia, thereby improving neuronal loss and behavioral deficits. Furthermore, results from monkey studies confirmed that ABL301 exhibited higher detection levels in brain tissue and cerebrospinal fluid compared to a monospecific antibody.
In January 2022, ABL Bio signed an exclusive collaboration and worldwide license agreement worth $1.06 billion with Sanofi for ABL301. After the agreement, both companies formed a joint research and development committee and have been collaborating on the development of ABL301. Currently, a Phase 1 clinical trial is underway in the United States to evaluate the safety and tolerability of ABL301.
Sang Hoon Lee, CEO of ABL Bio said, “We are pleased to present ABL301 at AD/PD 2025, where leading global experts in neurodegenerative diseases and various pharmaceutical and biotech companies gather,” and added, “The Phase 1 clinical trial of ABL301 is progressing smoothly in the United States. We hope that ABL301 will become a treatment that contributes to a better life for patients with Parkinson’s disease.”
Meanwhile, ABL Bio is developing various clinical and non-clinical assets based on its bispecific antibody platform ‘Grabody’. Clinical projects for 7 pipelines, including ABL301, ABL001, ABL111/givastomig, ABL503/ragistomig, ABL105, ABL202, and ABL103, are underway for different indications in various countries, including the United States, China, Australia, and Korea. In case of ABL001, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) to support the rapid development of this new drug candidate. In addition, ABL111/givastomig, co-developed with I-Mab, is expected to disclose the top-line data from the Phase 1b clinical trial in 2025, evaluating the triple combination therapy with nivolumab and chemotherapy. Meanwhile, ABL Bio is preparing to initiate clinical trials for ABL104. In addition, ABL Bio is continuously researching and developing several other product candidates, including bispecific antibody-drug conjugates (ADCs).